Название продукции:3,6-dichloro-4-methylpyridazine

IUPAC Name:3,6-dichloro-4-methylpyridazine

CAS:19064-64-3
Молекулярная формула:C5H4Cl2N2
Чистота:97%
Номер в каталоге:CM102253
Молекулярная масса:163

Упаковочная единица Доступно для заказа Цена ($) Количество
CM102253-100g in stock ƴŁ
CM102253-500g in stock Žǎƴ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:19064-64-3
Молекулярная формула:C5H4Cl2N2
Точка плавления:-
Smiles-код:CC1=CC(Cl)=NN=C1Cl
Плотность:
Номер в каталоге:CM102253
Молекулярная масса:163
Точка кипения:272.1°C
Номер Mdl:MFCD00006465
Хранение:Store at 2-8°C.

Category Infos

Pyridazines
Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.